Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2006-12-26
2006-12-26
Slobodyansky, Elizabeth (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S006120, C435S023000, C435S024000
Reexamination Certificate
active
07153679
ABSTRACT:
A novel arterial thrombosis risk factor comprising one or more of the identified mutants of coagulation factor VII-activating protease (FSAP) is described. In addition, diagnostic determination methods for detecting these mutants which are identified as risk factors are described.
REFERENCES:
patent: 5175087 (1992-12-01), Ranby et al.
patent: 5968759 (1999-10-01), Romisch et al.
patent: 2002/0110552 (2002-08-01), Roemisch et al.
patent: 2003/0077271 (2003-04-01), Roemisch et al.
patent: 2003/0124622 (2003-07-01), Roemisch et al.
patent: 2003/0215447 (2003-11-01), Roemisch et al.
patent: 2004/0063187 (2004-04-01), Roemisch et al.
patent: 2004/0186277 (2004-09-01), Roemisch et al.
patent: 2005/0032109 (2005-02-01), Roemisch et al.
patent: 2005/0202002 (2005-09-01), Roemisch et al.
patent: 199 26 531.3 (1999-06-01), None
patent: 199 03 693 (1999-10-01), None
patent: 100 23 923 (2000-12-01), None
patent: 199 37 218 (2001-02-01), None
patent: 199 37 219 (2001-02-01), None
patent: 100 36 641 (2002-02-01), None
patent: 0 952 215 (1999-10-01), None
patent: 1 033 405 (2000-09-01), None
patent: 1 059 359 (2000-12-01), None
patent: 1 074 615 (2001-02-01), None
patent: 1 074 616 (2001-02-01), None
patent: 1 182 258 (2006-02-01), None
N.-H. Choi-Miura et al., “Proteolytic Activation and Inactivation of the Serine Protease Activity of Plasma Hyaluronan Binding Protein,”Biol. Pharm. Bull., 24(5):448-452 (2001).
J. Willeit et al., “Marburg I Polymorphism of Factor VII-Activating Protease: A Prominent Risk Predictor of Carotid Stenosis,”Circulation, 107(5):667-670 (2003).
J. Römisch “Factor VII Activating Protease (FSAP): A Novel Protease in Hemostasis,”Biol. Chem., 383:1119-1124 (2002).
S. Kiechl & J. Willeit, “The Natural Course of Atherosclerosis. Part I: Incidence and Progression,”Arterioscler, Thromb. Vasc. Biol., 19:1484-90 (1999).
S. Kiechl & J. Willeit, “The Natural Course of Atherosclerosis. Part II: Vascular Remodeling,”Arterioscler. Thromb. Vasc. Biol., 19: 1491-8 (1999).
J. Willeit et al., “Distinct Risk Profiles of Early and Advanced Atherosclerosis. Prospective Results from the Bruneck Study,”Arterioscler. Thromb. Vasc. Biol., 20: 529-37 (2000).
S. Kiechl et al., “Chronic Infections and the Risk of Carotid Atherosclerosis. Prospective Results from a Large Population Study,”Circulation, 103: 1064-70 (2001).
S. Kiechl et al., “Body Iron Stores and the Risk Carotid Atherosclerosis. Prospective Results from the Bruneck Study,”Circulation, 96: 3300-7 (1997).
S. Kiechl et al., “Toll-like Receptor 4 Polymorphisms and Atherogenesis,”N. Engl. J. Med., 347: 185-92 (2002).
J. Römisch et al., “Quantitation of the Factor VII-and Single Chain Plasminogen Activator-Activating Protease in Plasmas of Healthy Subjects,”Blood Coagul. Fibrinolysis, 12: 375-83 (2001).
C. Kannemeier et al., “Factor VII and Single-Chain Plasminogen Activator-Activating Protease: Activation and Autoactivation of the Proenzyme,”Eur. J. Biochem., 268: 3789-96 (2001).
J. Roemisch et al., “The FrequentMarburg IPolymorphism Impairs the Pro-urokinase Activating Potency of the Factor VII-Activating Protease (FSAP),”Blood Coagul. Fibrinolysis, 13: 433-41 (2002).
T.C. Wilcosky & L.E. Chambless, “A Comparison of Direct Adjustment and Regression Adjustment of Epidemiologic Measures,”J. Chron. Dis., 38: 849-56 (1985).
N.H.- Choi-Miura, et al. “Purification and Characterization of a Novel Hyaluronan-Binding Protein (PHBP) from Human Plasma: It Has Three EGF, a Kringle and a Serine Protease Domain, Similar to Hepatocyte Growth Factor Activator”J. Biochem., 119(6)1157-65 (1996).
A. Hunfeld, et al. “Identification of the Thrombin-Like Activity of PCCs”Annals of Hematology,(76 Suppl. 1):A101 (1998).
A. Hunfeld, et al. “Detection of a Novel Plasma Serine Protease During Purification of Vitamin K-dependent Coagulation Factors”FEBS Letters, 456:290-94 (1999).
J. Römisch, et al. “A Protease Isolated from Plasma which Activates FVII in a Tissue Factor Independent Manner but Inactivates FV and FVIII”Annals of Hermatology, (78 Suppl. 1):A10 (1999).
J. Römisch, et al. “The FVII Activating Protease Mediates Fibrinolytic Effects Activating Single-Chain Plasminogen Activators”Annals of Hermatology, (78 Suppl. 1):A24 (1999).
J. Römisch, et al. “A Protease Isolated from Human Plasma Activating Factor VII Independent of Tissue Factor”Blood Coagul. Fibrinol., 10:471-479 (1999).
J. Römisch, et al. “The FVII Activating Protease Cleaves Single-Chain Plasminogen Activators”Haemostasis, (29):292-299 (1999).
T. Prins et al., “Cloning and characterization of a glutathione S-transferase homologue from the plant pathogenic fungusBotrytis cinerea,” Molecular Plant Pathology, 1: 169-178 (2000).
Doris, Pa, “Hypertension Genetics, Single Nucleotide Polymorphisms, and the Common Disease: Common Variant Hypothesis,”Hypertension, 39(Part II): 323-331 (2002).
Stephens, JC et al., “Haplotype Variation and Linkage Disequilibrium in 313 Human Genes,”Science, 293: 489-493 (2001).
Chakravarti, A., “Population Genetics—Making Sense out of Sequence,”Nature Genetics Supplement, 21: 56-60 (1999).
Cargill, M. et al., “Characterization of Single-Nucleotide Polymorphisms in Coding Regions of Human Genes,”Nature Genetics, 22: 231-238 (1999).
K. Laake et al., “Activation of Purified Plasma Factor VII By Human Plasmin, Plasma Kallikrein, And Activated Components of the Human Intrinsic Blood Coagulation System,”Thrombosis Research, vol. 5 (6): 759-772 (1974).
K. Hashimoto et al., “Cloning of the cDNA for a Mouse Homologue of Human PHBP: A Novel Hyaturonan-Binding Protein,”Biol. Pharm. Bulletin, vol. 20(11): 1127-1130 (1997).
J-I. Sumiya et al., “Isolation and Characterization of the Plasma Hyaturonan-Binding Protein (PHBP) Gene (HABP2),”J. Biochem., vol. 122: 983-990 (1997).
M. Etscheid et al., “Characterization of a Novel Serine Protease From Plasma,” (Abstract) (1999).
A. Vostrov et al., “Plasma Hyaturonan-binding Protein Is a Serine Protease,”J. Biological Chemistry, vol. 275 (30): 22978-22985 (2000).
Becker Margret
Doersam Volker
Feussner Annette
Kiechl Stefan
Knoblauch Bernd
Aventis Behring GmbH
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Slobodyansky Elizabeth
LandOfFree
Marburg I mutant of factor VII activating protease (FSAP) as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Marburg I mutant of factor VII activating protease (FSAP) as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Marburg I mutant of factor VII activating protease (FSAP) as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3712108